
Cytosorbents Corp CTSO.OQ CTSO.O is expected to show a fall in quarterly revenue when it reports results on May 14 for the period ending March 31 2025
The Princeton New Jersey-based company is expected to report a 8.0% decrease in revenue to $9.007 million from $9.79 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Cytosorbents Corp is for a loss of 7 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Cytosorbents Corp is $7.00, above its last closing price of $0.87.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.06 | -0.06 | -0.14 | Missed | -121.1 |
Sep. 30 2024 | -0.06 | -0.06 | -0.04 | Beat | 36.8 |
Jun. 30 2024 | -0.09 | -0.10 | -0.08 | Beat | 17.9 |
Mar. 31 2024 | -0.12 | -0.12 | -0.12 | Met | 0 |
Dec. 31 2023 | -0.10 | -0.14 | -0.13 | Beat | 5.5 |
Sep. 30 2023 | -0.15 | -0.14 | -0.21 | Missed | -52.2 |
Jun. 30 2023 | -0.11 | -0.11 | -0.14 | Missed | -24.4 |
Mar. 31 2023 | -0.13 | -0.13 | -0.17 | Missed | -34.2 |
This summary was machine generated May 12 at 20:42 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)